Literature DB >> 9241510

Salvage treatment of relapsing Wilms' tumour by autologous bone marrow transplantation.

C M Kullendorff1, A N Békássy.   

Abstract

Despite the remarkable success in treatment of Wilms' tumour there is still a small group who will suffer from relapse. The optimal therapy for relapsing Wilms tumour has not been determined. We have treated four children with high-dose chemotherapy (HDC) followed by stem-cell support known as autologous bone marrow transplantation (ABMT). The patients were two girls and two boys aged 1-9 years. The histology was favourable in 3 cases and unfavourable, clear cell sarcoma, in 1. The relapses were pulmonary in 2 cases and skeletal in 2 cases. There was no detectable disease prior to ABMT. After ABMT 2 children got further relapses and died. On the other hand 2 children had no further relapse and are alive and well 1.5-2.5 years later. Treatment with HDC and ABMT is complicated and expensive but may be of benefit and should be added to the treatment options in children with otherwise poor prognosis of Wilms' tumour.

Entities:  

Mesh:

Year:  1997        PMID: 9241510     DOI: 10.1055/s-2008-1071087

Source DB:  PubMed          Journal:  Eur J Pediatr Surg        ISSN: 0939-7248            Impact factor:   2.191


  2 in total

Review 1.  Position paper: Rationale for the treatment of children with CCSK in the UMBRELLA SIOP-RTSG 2016 protocol.

Authors:  Saskia L Gooskens; Norbert Graf; Rhoikos Furtwängler; Filippo Spreafico; Christophe Bergeron; Gema L Ramírez-Villar; Jan Godzinski; Christian Rübe; Geert O Janssens; Gordan M Vujanic; Ivo Leuschner; Aurore Coulomb-L'Hermine; Anne M Smets; Beatriz de Camargo; Sara Stoneham; Harm van Tinteren; Kathy Pritchard-Jones; Marry M van den Heuvel-Eibrink
Journal:  Nat Rev Urol       Date:  2018-02-27       Impact factor: 14.432

2.  Treatment and outcome of patients with relapsed clear cell sarcoma of the kidney: a combined SIOP and AIEOP study.

Authors:  S L Gooskens; R Furtwängler; F Spreafico; H van Tinteren; J de Kraker; G M Vujanic; I Leuschner; A Coulomb-L'Herminé; J Godzinski; G Schleiermacher; S Stoneham; C Bergeron; K Pritchard-Jones; N Graf; M M van den Heuvel-Eibrink
Journal:  Br J Cancer       Date:  2014-06-17       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.